Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab

NCT05886036 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05886036
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05886036 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
NORM: Nodular Lymphocyte-Predominant Hodgkin Lymphoma Patients Treated in a Randomized Phase 2 Trial With Either Rituximab or Mosunetuzumab
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
January 23, 2024
Completion date
October 31, 2028
Enrollment
70 (estimated)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

nodular lymphocyte predominant b-cell lymphoma, recurrent nodular lymphocyte predominant b-cell lymphoma, refractory nodular lymphocyte predominant b-cell lymphoma